GVR Report cover Asia Pacific Cell Therapy Market Size, Share & Trends Report

Asia Pacific Cell Therapy Market Size, Share & Trends Analysis Report By Use-type (Clinical-use, Research-use), By Therapy Type (Autologous, Allogeneic), And Segment Forecasts, 2021 - 2028

  • Report ID: GVR-4-68039-450-4
  • Number of Pages: 135
  • Format: Electronic (PDF)
  • Historical Range: 2017 - 2019
  • Industry: Healthcare

Report Overview

The Asia Pacific cell therapy market size was valued at USD 959.8 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.9% from 2021 to 2028. The development of stem cell banking facilities and the resultant increase in stem cell production is expected to improve the volumetric capabilities of the market at a regional and country level. This, in turn, is anticipated to drive the market.

Malaysia cell therapy market size for clinical-use, by therapeutic area, 2017 - 2028 (USD Million)

Moreover, advancements in the therapy landscape with respect to their efficiency and manufacturing are some other major drivers of the market. The outbreak of the SARS-CoV-2 pandemic has further driven the market as currently, there are no robust treatments for infection treatment, particularly in severe cases. A broad range of differences in the clinical symptoms of patients is primarily due to the genomic variations. Therefore, personalized treatment including cell therapies is recognized as a viable treatment approach in improving these symptoms.

Furthermore, according to some studies and evidence, it was found that increased levels of cytokines and chemokines that target lung tissue are due to some etiological factors. Mesenchymal Stem Cell (MSC)-derived exosomes are considered to have potential therapeutic activity in treating SARS-CoV-2 pneumonia due to their anti-inflammatory activity, ability to induce tissue regeneration, and immune-modulating capacity.

Also, rising clinical studies on exosomes to treat COVID-19 are expected to boost the market growth over the forecast period. For instance, Shanghai Public Health Clinical Center collaborated with Wuhan Jinyintan Hospital and Cellular Biomedicine Group Ltd. in February 2020 to perform clinical trials for inhalation of MSCs-derived exosomes to treat coronavirus. A rise in approval, as well as adoption of regenerative medicine across several Asian countries, is expected to boost the revenue generation of the market.

For instance, In January 2021, Daiichi Sankyo Company, Limited received MHLW approval for Yescarta in Japan. With this, Japan became the only East-Asian nation with commercialized Kymriah and Yescarta for clinical use. Similarly, in October 2020, Novartis received MHLW approval for Foundation for Biomedical Research and Innovation at Kobe (FBRI) to supply and produce Kymriah in Japan. This is expected to bring a manufacturing network that bridges the gap between demand and supply of advanced cell therapies in Asia.

Use-type Insights

The research-use segment dominated the market and accounted for the largest revenue share of 87.0% from 2021 to 2028. Currently, stem and non-stem cells are primarily being used for research projects, which have led to the highest revenue share of USD 650.2 million in 2020. Stem cell research emerged as a significant field in several Asia Pacific countries. The notable investment in programs and facilities that are designed to intensify competitiveness in the drive to decipher clinical applications of stem cells over the past decade is proof of growth in this region.

Furthermore, global stem cell-based companies have a widespread presence across the Asian market, which positively impacts the segment growth. STEMCELL Technologies, Inc. operates in four locations in Asia: Shanghai, Beijing, Singapore, and Korea. Currently, there is a limited number of approved stem and non-stem cell therapies in the market, which can be attributed to the low penetration of this segment in 2020.

Some examples of cell therapies approved for clinical applications are Kymriah, Yescarta, BREYANZI, Cellgram-AMI, Cupistem, CARTISTEM, Invossa, Prochymal, and others. Nonetheless, the success of these approved products has encouraged significant investment flow by the companies in this segment, resulting in a notable growth rate of the segment. For instance, in November 2020, JW Therapeutics, a China-based cell therapy company, launched a 300 million IPO and is anticipated to become the first company to launch CAR T therapy products in China.

Therapy Type Insights

The autologous therapies segment dominated the APAC cell therapy market and held the largest revenue share of 55.0% in 2020. The segment is expected to maintain its dominance during the forecast period. In March 2021, Breyanzi, a CD19-directed autologous CAR T therapy designed for the treatment of patients with relapsed or refractory (R/R) large B-cell lymphoma and R/R follicular lymphoma received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW). Such approvals in the space have attributed to the larger share of this segment.

Furthermore, a data center in Japan is engaged in the nationwide collection of donor-, recipient-, and outcomes-related data. This data center is anticipated to emerge as one of the main data providers for the new cell therapy databases in the country, thereby positively impacting segment growth. On the other hand, the allogeneic therapies segment is anticipated to register relatively slow growth in 2021-2028 due to the high cost associated with allogeneic transplant procedures and rising approvals of autologous CAR-T therapies.

Asia Pacific cell therapy market share, by therapy type, 2020 (%)

However, allogeneic CAR T cell therapies are receiving traction as a more profitable business by several biopharma companies, compared to existing manufacturing and business models. The allogeneic therapies are also appropriate for the standard model of biopharmaceutical manufacturing, wherein a master or universal cell is deployed to manufacture therapeutics at large scales, which can then be administered to multiple patients. Thus, improvement in allogeneic T-cell therapies can offer significant growth opportunities to biopharma companies operating in this space.

Country Insights

Japan dominated the market and accounted for the largest revenue share of 17.1% in 2020. This can be attributed to its fast growth as a hub for research on regenerative medicine. The country has emerged as a hub for cellular therapy research, largely driven by support from government bodies. Government bodies have recognized regenerative medicine, including cellular therapy, as vital elements in the country’s strategy to accelerate economic growth.

With the recent approval of Novartis’s CAR-T therapy- Kymriah in Singapore in March 2021, the country is anticipated to register the fastest growth, followed by India and China. Rapid expansion in the field of stem cell research, along with changing regulations, has accelerated cell therapy development in the country. Furthermore, collaborations among hospitals, startups, and academic institutes are anticipated to promote the rapid development and adoption of CAR T cell therapy in India.

The presence of companies such as Immuneel Therapeutics, which is engaged in the establishment of a focused hub for cell therapy in the country, is driving investment in the Indian market. The company’s efforts for cell therapy development are part of the Make in India initiative to make this advanced therapy easily accessible to patients at a reasonable price.

The initiative also aimed at providing access to any global patient seeking this therapy in India at a relatively lower cost than in other countries. This will facilitate medical tourism in India, thereby driving market growth in the country.

Key Companies & Market Share Insights

Global and homegrown companies are engaged in securing regulatory approvals for their cell therapy products to expand the market reach of products across Asian markets. For instance, In March 2021, Novartis received Health Sciences Authority (HAS approval for the commercialization of Kymriah in Singapore. This enabled Singapore General Hospital (SGH) to become the first Southeast Asian treatment center to use Kymriah for treatment of young adult r/r B-cell ALL and adult r/r DLBCL. Some of the prominent players in the Asia Pacific cell therapy market include:

  • Kolon TissueGene, Inc.

  • JCR Pharmaceuticals Co., Ltd.


  • PHARMICELL Co., Ltd.


  • Bristol-Myers Squibb Company

  • Novartis AG

  • Gilead Sciences, Inc.

  • Curocell, Inc.

  • JW Therapeutics (Shanghai) Co., Ltd.


Asia Pacific Cell Therapy Market Report Scope

Report Attribute


Market size value in 2021

USD 1,166.1 million

Revenue forecast in 2028

USD 2.9 billion

Growth rate

CAGR of 14.9% from 2021 to 2028

Base year for estimation


Historical data

2017 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Use-type, therapy type, country

Country scope

Japan; China; India; Malaysia; South Korea; Philippines; Australia; Indonesia; Singapore

Key companies profiled

Kolon TissueGene, Inc.; JCR Pharmaceuticals Co., Ltd.; MEDIPOST; PHARMICELL Co., Ltd.; ANTEROGEN. CO., LTD; Bristol-Myers Squibb Company; Novartis AG; Gilead Sciences, Inc.; Curocell, Inc.; JW Therapeutics (Shanghai) Co., Ltd.; Stempeutics Research Pvt. Ltd.

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the Asia Pacific cell therapy market report on the basis of use-type, therapy type, and country:

  • Use-type Outlook (Revenue, USD Million, 2017 - 2028)

    • Clinical-use

      • By Therapeutic Area

        • Malignancies

        • Muscoskeletal Disorders

        • Autoimmune Disorders

        • Dermatology

        • Others

      • By Cell Type

        • Stem Cell Therapies

          • BM, Blood, & Umbilical Cord-derived Stem Cells/ Mesenchymal Stem Cells

          • Adipose derived cells

          • Others

        • Non-stem Cell Therapies

    • Research-use

  • Therapy Type Outlook (Revenue, USD Million, 2017 - 2028)

    • Allogeneic Therapies

    • Autologous Therapies

  • Country Outlook (Revenue, USD Million, 2017 - 2028)

    • China

    • Japan

    • India

    • Malaysia

    • South Korea

    • Philippines

    • Australia

    • Indonesia

    • Singapore

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.